European registry for newly diagnosed AL amyloidosis
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study collects information and samples from people newly diagnosed with AL amyloidosis who have not yet received treatment. It aims to improve how this rare disease is diagnosed and managed across Europe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have AL amyloidosis (light chain amyloidosis).
- You have not had any prior treatment for this condition.
- You are 18 years of age or older.
- You agree to sign a consent form and are willing to be followed at a participating center.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from adults with systemic AL amyloidosis to better understand the disease and outcomes. Because it includes pre-treatment records and follows people over time, it may help future patients by improving knowledge of how AL amyloidosis progresses and responds to care.
This study collects blood and tissue samples and health data from people with amyloidosis to build a biobank and registry. Researchers hope this will help improve future diagnosis and treatment.
This study is for people who are newly diagnosed with either a very early blood condition (MGUS or smoldering myeloma) or AL amyloidosis, and who have not yet had treatment. It aims to help doctors better diagnose and manage these conditions in Italy.
This study creates a registry for people diagnosed with systemic amyloidosis in Hungary. It helps doctors better understand the condition by collecting medical history and tracking outcomes over time.
This early-stage trial tests a new drug called anselamimab for AL amyloidoma—a rare condition where abnormal protein deposits form tumors in one part of your body. The study aims to see if this drug can help shrink or control these deposits in patients who have a visible, removable tumor.
This study tests a new drug that targets two proteins on the cells causing amyloidosis, aiming to reduce the harmful protein buildup in the body. It is for people who have just been diagnosed with this condition and have not yet had other treatments for it.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.